Monday - June 22, 2026

Category Archives: Science

New Free Privacy Focused Android App Allows a Record Breaking 70 Billion Parameter AI Model to Run Entirely Offline on High-End Android Devices

Stephen J. Pereira, Lead Developer of the project said: “Our software is a bit like a cassette player for optimised AI models, with the different available LLMs considered a collection of cassettes. Android makes that idea even more powerful because … Continue reading →

Multiple Sclerosis Market is Expected to Surpass USD 33 Billion by 2036, Driven by Rising Disease Burden and Emerging BTK Inhibitor Therapies | DelveInsight

The Multiple Sclerosis Market is witnessing substantial growth driven by the increasing diagnosed prevalence of the disease, growing adoption of high-efficacy disease-modifying therapies, advancements in treatment delivery systems, and the emergence of novel therapies targeting progressive forms of multiple sclerosis. … Continue reading →

Polymyalgia Rheumatica Market is Expected to Witness Robust Growth by 2036 Driven by Rising Disease Burden and Emerging Targeted Therapies | DelveInsight

The Polymyalgia Rheumatica Market is expected to witness notable growth during the forecast period, driven by increasing disease prevalence, improved diagnosis rates, and rising awareness among healthcare providers and patients. The growing adoption of targeted biologics, demand for steroid-sparing treatment … Continue reading →

Persistent Epithelial Defect Market is Anticipated to Witness Significant Growth by 2036 Driven by Rising Disease Burden and Emerging Regenerative Therapies | DelveInsight

The Persistent Epithelial Defect (PED) Market is expected to experience substantial growth through 2036, fueled by increasing disease awareness, growing incidence of ocular surface disorders, unmet clinical needs, and the anticipated launch of innovative regenerative therapies. Emerging Persistent Epithelial Defect … Continue reading →

Chronic Spontaneous Urticaria Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Chronic Spontaneous Urticaria Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Chronic Spontaneous Urticaria pipeline landscape. It covers the Chronic Spontaneous Urticaria Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Chronic Kidney Disease Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Chronic Heart Failure Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Chronic Heart Failure Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Chronic Heart Failure pipeline landscape. It covers the Chronic Heart Failure Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Spinal Muscular Atrophy Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Spinal Muscular Atrophy Pipeline Insight 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Spinal Muscular Atrophy pipeline landscape. It covers the Spinal Muscular Atrophy pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Soft Tissue Sarcoma Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Soft Tissue Sarcoma Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the Soft Tissue Sarcoma Marketed and Pipeline Drugs profiles, including clinical and nonclinical stage … Continue reading →